TrialBreast cancer (Tokyo, Japan)2026
Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancer.
Tsuguo Iwatani et al.PubMed ↗Publisher ↗
No numbers read from the abstract.